Sangamo Therapeutics, Inc.SS

Sangamo Therapeutics, Inc.

0.8700USDR
+0.0034+0.39%
Last update at 22:33 GMT
0.8700USD
0.00000.00%
No tradesPost-marketLast update at 22:27 GMT
See on Supercharts

SGMO fundamentals

Key facts

Market capitalization‪195.50 M‬USD
Basic EPS (TTM)−0.52USD
Founded1995
CEOAlexander D. Macrae
About

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Ownership
‪‪224.71 M‬‬
Free Float shares
‪‪214.59 M‬‬ (95.5%)
Closely held shares
‪‪10.12 M‬‬ (4.5%)
Free Float shares
‪‪214.59 M‬‬ (95.5%)
Closely held shares
‪‪10.12 M‬‬ (4.5%)
Capital structure
Market cap
‪‪195.50 M‬‬
Debt
‪‪30.57 M‬‬
Cash & equivalents
‪‪41.92 M‬‬
Enterprise value
‪‪184.15 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪195.50 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
3.15x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
3.15x
Valuation ratios
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪1.70‬
‪3.40‬
‪5.10‬
‪6.80‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−12,000%‬
‪−8,000%‬
‪−4,000%‬
‪0%‬
‪4,000%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−70.00 M‬‬
‪‪−35.00 M‬‬
‪0.00‬
‪‪35.00 M‬‬
‪‪70.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−30.00 M‬‬
‪‪−20.00 M‬‬
‪‪−10.00 M‬‬
‪0.00‬
‪‪10.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−24.00 M‬‬
‪‪−16.00 M‬‬
‪‪−8.00 M‬‬
‪0.00‬
‪‪8.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Epigenetic
By country
Period: 2024
United States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪13.00 M‬‬
‪‪26.00 M‬‬
‪‪39.00 M‬‬
‪‪52.00 M‬‬
Actual
Estimate
Earnings
Next:Apr 30, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪−0.30‬
‪−0.20‬
‪−0.10‬
‪0.00‬
‪0.10‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

SGMO does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−60.00 M‬‬
‪‪−30.00 M‬‬
‪0.00‬
‪‪30.00 M‬‬
‪‪60.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪15.00 M‬‬
‪‪30.00 M‬‬
‪‪45.00 M‬‬
‪‪60.00 M‬‬
Assets
Liabilities